said a federal judge has denied a bid by Denmark's
to halt sales of the inhaled insulin Exubera.
Novo Nordisk, which is working on its own inhaled insulin,
sued Pfizer in August for patent infringement. On Thursday, a judge in New York rejected Novo Nordisk's request for a preliminary injunction until the patent suit is resolved. A Pfizer spokesman said a trial date hasn't been set.
Pfizer developed Exubera with
Approved by the FDA in January, Exubera, a dry powder form of insulin, has been
reaching markets slowly since July.
Pfizer says a full-scale launch of the drug to primary care physicians will begin in January.
Novo Nordisk is working on AERx, an inhaled form of liquid insulin, using technology developed by
. Analysts say it will still take about four years for this product to be available.